3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion

ConditionIUD
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-55
SponsorWomen's College Hospital

About this trial

Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.

Eligibility criteria

Qualifiers

Patients with a uterus.

Ages 18 to 55 years.

Undergoing any intrauterine device (IUD) insertion.

English-speaking participants.

Disqualifiers

Inability to provide informed consent.

Confirmed pregnancy.

Use of pain medication other than NSAIDs or acetaminophen (e.g., opioids, benzodiazepines, muscle relaxants) within 24 hours prior to the intervention.

Use of cannabis within 24 hours prior to the intervention.

Trial design

Treatments tested in this trial

  • Methoxyflurane
  • Saline

Treatment groups

110 Participants
are divided into 2 treatment groups

Sponsors and collaborators